New #1 treatment in its class

AS OF 8/6/2021*

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one
prescribed,
number one in new prescriptions, and more neurologists selected as
brand of choice

Dissolving the line between ACUTE &
PREVENTIVE treatment for migraines1,2

Ellie W. Actual Nurtec ODT Patient

The first
and only
medication proven:

FAST
  • ONE rapidly dissolving tablet that works quickly to resolve pain and return many patients back to normal activities in 1 hour1,3-5
  • Demonstrated preventive effect within 1 week for many patients6,*
LASTS...
  • Treats or prevents for up to 48 hours at a time for many patients1,3,7
  • Reduction in mean monthly migraine days (MMDs) for many patients through 12 weeks of treatment1,2
see the data

So you
can

TREAT PREVENT
see patient profiles order samples access support

Back to normal activities = return to normal function

*Exploratory analysis. Subjects had ≥1 day of efficacy data in the observation period and in the first week of the double-blind treatment period.6

Study designs

For the acute indication, Nurtec ODT was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), with co‑primary endpoints at 2 h for Nurtec ODT vs placebo: pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptoms (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%; P=.001).1

For the preventive indication, rimegepant 75 mg was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 695 patients (rimegepant 75 mg, n=348; placebo, n=347) with the primary endpoint being change from baseline in the mean number of monthly migraine days during weeks 9‑12 (-4.3 vs -3.5, P=.01).1

A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).1,8

See full study design

Over 230 million insured individuals
have access to Nurtec ODT*

Nurtec ODT is the exclusive oral CGRP receptor antagonist on Anthem's
national commercial formulary*

Nurtec ODT is a Preferred oral CGRP receptor antagonist on Aetna's
national commercial formulary*

Nurtec ODT is a Preferred oral CGRP receptor antagonist on Cigna's
national commercial formulary*

Find specific formulary coverage in your area.

Auto-locate

Error: Please provide a valid ZIP code.

OR

Error: Please provide a valid NPI number.

Error: Please provide either a valid ZIP code or an
NPI number.

*Managed Markets Insights & Technology LLC as of 11/30/2021

Ellie's Migraine Story

Anytime I have a
stressful
exam or my
period is
coming up,
I know I can
count on
Nurtec ODT to
prevent
my migraines.

Ellie W
Actual Nurtec ODT Patient
Individual results may vary.

How Khloé took control of her
migraines with Nurtec ODT

I can turn to one medication for migraine relief or prevention.

Khloé Kardashian
Actual Nurtec ODT Patient
Individual results may vary.

Learn the Latest

Expert speaker events are happening in your area.
Find out more and register here

register here

Nurtec® OneSource

Getting support and savings† for you and your patients has never been easier

learn more

†Eligible for some patients.

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 3. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 4. Data on File. RIM108. Biohaven Pharmaceuticals Inc. 5. Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: 61st Annual Scientific Meeting of the American Headache Society; Philadelphia, PA. Session IOR05; July 11, 2019. 6. Lipton RB, Croop R, Jensen CM, et al. Rapid Decrease in Migraine Days With Rimegepant: Results From a Post Hoc Analysis of a Phase 2/3, Randomized, Double‑Blind, Placebo‑Controlled Trial. Virtual Poster presented at: American Headache Society 2021 Annual Meeting; June 3-6, 2021. 7. Data on File. RIM118. Biohaven Pharmaceuticals Inc. 8. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; 2020.